Cargando…
Benign prostatic hyperplasia and subsequent risk of bladder cancer
We evaluated the risk of bladder cancer in a cohort of 79 280 Swedish men hospitalised for benign prostatic hyperplasia (BPH), identified in the Swedish Inpatient Register between 1964 and 1983 and followed until 1989 via multiple record linkages with nationwide data on cancer registry, death and em...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360186/ https://www.ncbi.nlm.nih.gov/pubmed/17473820 http://dx.doi.org/10.1038/sj.bjc.6603730 |
_version_ | 1782152985786187776 |
---|---|
author | Kang, D Chokkalingam, A P Gridley, G Nyren, O Johansson, J E Adami, H O Silverman, D Hsing, A W |
author_facet | Kang, D Chokkalingam, A P Gridley, G Nyren, O Johansson, J E Adami, H O Silverman, D Hsing, A W |
author_sort | Kang, D |
collection | PubMed |
description | We evaluated the risk of bladder cancer in a cohort of 79 280 Swedish men hospitalised for benign prostatic hyperplasia (BPH), identified in the Swedish Inpatient Register between 1964 and 1983 and followed until 1989 via multiple record linkages with nationwide data on cancer registry, death and emigration. Standardised incidence ratios (SIRs), the ratios of the observed to the expected numbers of incident bladder cancers, were used to calculate the risk associated with BPH. The expected number was calculated by multiplying the number of person-years by the age-specific cancer incidence rates in Sweden for each 5-year age group and calendar year of observation. Analyses were stratified by BPH treatment, latency, calendar year and presence of genitourinary (GU) comorbid conditions. After excluding the first 3 years of follow-up after the index hospitalisation, we observed 506 incident bladder cancer cases during follow-up in the cohort. No overall increased risk of bladder cancer was apparent in our main analysis involving the entire BPH cohort. However, among BPH patients with transurethral resection of the prostate (TURP), there was an increased risk in all follow-up periods; SIRs of bladder cancer during years 4–6 of follow-up was 1.22 (95% confidence interval=1.02–1.46), 1.32 for 7–9 years of follow-up, and 1.47 for 10–26 years of follow-up. SIRs of bladder cancer among TURP-treated BPH patients were particularly elevated among those with comorbid conditions of the GU tract (e.g., stone, infection, etc.); 1.72, 1.74 and 2.01 for 4–6, 7–9, 10–26 years of follow-up, respectively, and also for those whose diagnoses occurred before 1975, when TURP was more likely to be performed by a urologist than a general practitioner: 1.87, 1.90 and 1.74, respectively. These findings suggest that BPH overall is not associated with bladder cancer risk. However, among men treated with TURP, particularly those with other comorbid GU tract conditions, risk of bladder cancer was elevated. |
format | Text |
id | pubmed-2360186 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23601862009-09-10 Benign prostatic hyperplasia and subsequent risk of bladder cancer Kang, D Chokkalingam, A P Gridley, G Nyren, O Johansson, J E Adami, H O Silverman, D Hsing, A W Br J Cancer Epidemiology We evaluated the risk of bladder cancer in a cohort of 79 280 Swedish men hospitalised for benign prostatic hyperplasia (BPH), identified in the Swedish Inpatient Register between 1964 and 1983 and followed until 1989 via multiple record linkages with nationwide data on cancer registry, death and emigration. Standardised incidence ratios (SIRs), the ratios of the observed to the expected numbers of incident bladder cancers, were used to calculate the risk associated with BPH. The expected number was calculated by multiplying the number of person-years by the age-specific cancer incidence rates in Sweden for each 5-year age group and calendar year of observation. Analyses were stratified by BPH treatment, latency, calendar year and presence of genitourinary (GU) comorbid conditions. After excluding the first 3 years of follow-up after the index hospitalisation, we observed 506 incident bladder cancer cases during follow-up in the cohort. No overall increased risk of bladder cancer was apparent in our main analysis involving the entire BPH cohort. However, among BPH patients with transurethral resection of the prostate (TURP), there was an increased risk in all follow-up periods; SIRs of bladder cancer during years 4–6 of follow-up was 1.22 (95% confidence interval=1.02–1.46), 1.32 for 7–9 years of follow-up, and 1.47 for 10–26 years of follow-up. SIRs of bladder cancer among TURP-treated BPH patients were particularly elevated among those with comorbid conditions of the GU tract (e.g., stone, infection, etc.); 1.72, 1.74 and 2.01 for 4–6, 7–9, 10–26 years of follow-up, respectively, and also for those whose diagnoses occurred before 1975, when TURP was more likely to be performed by a urologist than a general practitioner: 1.87, 1.90 and 1.74, respectively. These findings suggest that BPH overall is not associated with bladder cancer risk. However, among men treated with TURP, particularly those with other comorbid GU tract conditions, risk of bladder cancer was elevated. Nature Publishing Group 2007-05-07 2007-05-01 /pmc/articles/PMC2360186/ /pubmed/17473820 http://dx.doi.org/10.1038/sj.bjc.6603730 Text en Copyright © 2007 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Epidemiology Kang, D Chokkalingam, A P Gridley, G Nyren, O Johansson, J E Adami, H O Silverman, D Hsing, A W Benign prostatic hyperplasia and subsequent risk of bladder cancer |
title | Benign prostatic hyperplasia and subsequent risk of bladder cancer |
title_full | Benign prostatic hyperplasia and subsequent risk of bladder cancer |
title_fullStr | Benign prostatic hyperplasia and subsequent risk of bladder cancer |
title_full_unstemmed | Benign prostatic hyperplasia and subsequent risk of bladder cancer |
title_short | Benign prostatic hyperplasia and subsequent risk of bladder cancer |
title_sort | benign prostatic hyperplasia and subsequent risk of bladder cancer |
topic | Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360186/ https://www.ncbi.nlm.nih.gov/pubmed/17473820 http://dx.doi.org/10.1038/sj.bjc.6603730 |
work_keys_str_mv | AT kangd benignprostatichyperplasiaandsubsequentriskofbladdercancer AT chokkalingamap benignprostatichyperplasiaandsubsequentriskofbladdercancer AT gridleyg benignprostatichyperplasiaandsubsequentriskofbladdercancer AT nyreno benignprostatichyperplasiaandsubsequentriskofbladdercancer AT johanssonje benignprostatichyperplasiaandsubsequentriskofbladdercancer AT adamiho benignprostatichyperplasiaandsubsequentriskofbladdercancer AT silvermand benignprostatichyperplasiaandsubsequentriskofbladdercancer AT hsingaw benignprostatichyperplasiaandsubsequentriskofbladdercancer |